NICE ticks box on final Bydureon recommendation
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has said that it is issuing its final draft guidance to the NHS on Lilly/Amylin's GLP1-agonist, Bydureon (exenatide extended-release).